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The FDA approved the first HIV protease inhibitor for the treatment of AIDS, 
Saquinavir in 1995. With other anti-HIV drugs, it can reduce the number of 
virus in the patient and can also reduce the chance of the infection of virus 
related to the AIDS. 
The pyridine bis (oxazoline) compaund has been widly used in asymmetric 
catalysis since 1989. So it is important to research them.  
On the basis of published results, Saquinavir and chiral pyridine bis 
(oxazoline) ligand (VI) have been synthesized from L-phenylalanine which 
acts as both chiral source and starting material through a series of approaches. 
In addition, we demonstrate the effectiveness of the ligand in a typical 
asymmetric benchmark-reaction, the diethylzinc addition to benzaldehyde.  
Synthesis of Saquinavir aiming at production 
L-phenylalanine was protected by methoxycarbonyl, subsequently through a 
one-carbon homogation and a diastereoselective reaction to form the alcohol 
chial center, ring closure to epoxide, coupling with the Decahydroisoquinoline 
derivative, followed by deprotection to give the core intermediate (III), finally 
coupling with quinargine (II) to provide Saquinavir (10 steps, overall yield: 
31.9%). 
Synthesis of pyridine bis (oxazoline) ligand 
Pyridine bisamide (V) was synthesized by cross-Claisen condensation using 
N-protected amino acid ester to obtain β -ketoester, diastereoselective 
reaction to form the alcohol chial center, deprotection to give the key amino 
alcohol (IV), coupling with pyridine-2,6-dicarboyl dichloride. Pyridine bis 
(oxazoline) ligand was provided using TBS as protectional group, converted 
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employed and evaluated in the NiCl B2 B•6HB2 BO-catalyzed addition of diethylzinc 
to benzaldehyde. Enantioselectivity up to 88% was obtained. Herein, we 
firstly disclosed a novel method to synehesize Pyridine bis (oxazoline) ligand 
which contain active group in position of C-5’ and firstly confirmed four 
compounds’ crystal structure by X-ray diffration.  
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第一章  前    言 

















第一节  抗艾滋病药物沙奎那韦的合成 
艾 滋 病 全 中 文 译 名 “ 获 得 性 免 疫 缺 陷 综 合 症 ”(Acquired 
Immunodeficiency Syndrome AIDS)，是一种使人体免疫功能缺损的疾病。
艾滋病毒（Human Immunodeficiency Virus HIV）自身能产生三种酶－逆
转录酶、蛋白酶和整合酶，以帮助 HIV 突破人体内的免疫防线，复制、
感染、生存下来，并破坏人体的免疫功能。 




























































































































































Scheme 1. 1 
 
第二节 C2-对称的手性二噁唑啉吡啶类配体的合成 




C2- 对 称 的 手 性 二 噁 唑 啉 吡 啶 类 化 合 物  (pyridine-2,6- bis 
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第二章  沙奎那韦的合成 
 
第二章   沙奎那韦的合成 
第一节 文献回顾 
2.1.1 沙奎那韦的合成方法分析 
第一种途径：直接利用手性硫化合物 8 与十氢异喹啉衍生物 9 反应生 
成物 6，接下来与含硫化合物连接得到核心片断 5，再利用两片段连接法
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DCC = N C N
             
Scheme 2. 2 
第二种途径：从 L-苯丙胺酸 12 出发，先合成关键中间体 11 或它的
类似物，然后与十氢异喹啉衍生物 9 反应生成核心片断 5，再利用两片段































































Scheme 2. 3   沙奎那韦的逆合成分析－2  
Gohring等2 用价廉易得的L-苯丙氨酸为原料，用甲氧羰基保护氨基得
13, 紧接着发生氯甲基化反应形成氯甲基酮 14，再利用MPV反应还原得
氯乙醇类化合物 15，脱去氯化氢后与片断 9 连接，去保护可得核心片断 5。
后利用DCC作偶联试剂连接另一片断 2，完成了沙奎那韦的合成 
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